[go: up one dir, main page]

WO2008014386A3 - Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique - Google Patents

Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique Download PDF

Info

Publication number
WO2008014386A3
WO2008014386A3 PCT/US2007/074448 US2007074448W WO2008014386A3 WO 2008014386 A3 WO2008014386 A3 WO 2008014386A3 US 2007074448 W US2007074448 W US 2007074448W WO 2008014386 A3 WO2008014386 A3 WO 2008014386A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
treatment
growth factor
receptor antagonists
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/074448
Other languages
English (en)
Other versions
WO2008014386A2 (fr
Inventor
Eric Rowinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200870603A priority Critical patent/EA200870603A1/ru
Priority to AU2007279261A priority patent/AU2007279261A1/en
Priority to BRPI0712368-0A priority patent/BRPI0712368A2/pt
Priority to EP07813400A priority patent/EP2043688A4/fr
Priority to JP2009522001A priority patent/JP2009544736A/ja
Priority to MX2008016187A priority patent/MX2008016187A/es
Priority to CA002654911A priority patent/CA2654911A1/fr
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of WO2008014386A2 publication Critical patent/WO2008014386A2/fr
Publication of WO2008014386A3 publication Critical patent/WO2008014386A3/fr
Priority to TNP2008000512A priority patent/TNSN08512A1/en
Priority to NO20085182A priority patent/NO20085182L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés de thérapie de combinaison pour traiter des tumeurs pédiatriques par l'administration d'un antagoniste de EGFR et d'un agent chimiothérapeutique. L'invention concerne également des procédés qui comprennent le traitement de tumeurs pédiatriques réfractaires.
PCT/US2007/074448 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique Ceased WO2008014386A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2007279261A AU2007279261A1 (en) 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
BRPI0712368-0A BRPI0712368A2 (pt) 2006-07-27 2007-07-26 método para inibir o crescimento de um tumor em um paciente pediátrico
EP07813400A EP2043688A4 (fr) 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique
JP2009522001A JP2009544736A (ja) 2006-07-27 2007-07-26 小児患者における腫瘍の上皮増殖因子受容体アンタゴニストによる治療
MX2008016187A MX2008016187A (es) 2006-07-27 2007-07-26 Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico.
EA200870603A EA200870603A1 (ru) 2006-07-27 2007-07-26 Лечение опухолей у педиатрических пациентов антагонистами рецептора эпидермального фактора роста
CA002654911A CA2654911A1 (fr) 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pediatriques avec des antagonistes des recepteurs du facteur de croissance epidermique
NO20085182A NO20085182L (no) 2006-07-27 2008-12-11 Behandling av tumorer hos pediatrikse pasienter med antagonister mot epidermal vekstfaktorresptor
TNP2008000512A TNSN08512A1 (en) 2006-07-27 2008-12-11 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27
US60/833,487 2006-07-27

Publications (2)

Publication Number Publication Date
WO2008014386A2 WO2008014386A2 (fr) 2008-01-31
WO2008014386A3 true WO2008014386A3 (fr) 2008-07-03

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/074448 Ceased WO2008014386A2 (fr) 2006-07-27 2007-07-26 Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique

Country Status (15)

Country Link
EP (1) EP2043688A4 (fr)
JP (1) JP2009544736A (fr)
KR (1) KR20090033841A (fr)
CN (1) CN101484186A (fr)
AU (1) AU2007279261A1 (fr)
BR (1) BRPI0712368A2 (fr)
CA (1) CA2654911A1 (fr)
CR (1) CR10486A (fr)
EA (1) EA200870603A1 (fr)
EC (1) ECSP089011A (fr)
MX (1) MX2008016187A (fr)
NO (1) NO20085182L (fr)
TN (1) TNSN08512A1 (fr)
WO (1) WO2008014386A2 (fr)
ZA (1) ZA200810600B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011750A (es) * 2019-03-27 2021-12-10 Nat Res Council Canada Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COMBS ET AL.: "Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and termozolomide (GERT)-phase I/II trial: study protocol", BMC CANCER, vol. 6, no. 133, 18 May 2006 (2006-05-18), pages 1 - 9, XP021016124 *
CUNNINGHAM ET A.: "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer", N. ENG. J. MED., vol. 351, no. 4, 22 July 2004 (2004-07-22), pages 337 - 345, XP008075821 *
DAW ET AL.: "Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study", J. CLIN. ONCOL., vol. 23, no. 25, 1 September 2005 (2005-09-01), pages 6172 - 6180, XP008100098 *
ELLER ET AL.: "Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme", NEUROSURGERY, vol. 51, no. 4, October 2002 (2002-10-01), pages 1005 - 1013, XP008100096 *
ELLER ET AL.: "Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo", NEUROSURGERY, vol. 56, no. 1, 2005, pages 155 - 162, XP008100097 *
HO ET AL.: "Proliferation of human neuroblastoma mediated by the epidermal growth factor receptor", CANCER RES., vol. 65, no. 21, 1 November 2005 (2005-11-01), pages 9868 - 9875, XP008100099 *
See also references of EP2043688A4 *

Also Published As

Publication number Publication date
MX2008016187A (es) 2009-01-20
ECSP089011A (es) 2009-01-30
NO20085182L (no) 2009-04-24
EP2043688A2 (fr) 2009-04-08
CA2654911A1 (fr) 2008-01-30
TNSN08512A1 (en) 2010-04-14
CN101484186A (zh) 2009-07-15
ZA200810600B (en) 2009-11-25
EA200870603A1 (ru) 2009-06-30
AU2007279261A1 (en) 2008-01-31
BRPI0712368A2 (pt) 2012-06-05
KR20090033841A (ko) 2009-04-06
WO2008014386A2 (fr) 2008-01-31
CR10486A (es) 2009-02-23
JP2009544736A (ja) 2009-12-17
EP2043688A4 (fr) 2009-11-11

Similar Documents

Publication Publication Date Title
EP2046973A4 (fr) Procédés d'identification, d'évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
WO2008077077A3 (fr) Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade
IL205960A0 (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
WO2010068866A3 (fr) Particules thérapeutiques pour administration parentérale, et procédés de fabrication et d'utilisation associés
EP2712930A3 (fr) Marqueurs pharmacodynamiques par induction alpha d'interféron
HK1047236A1 (zh) 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
EP3208615A3 (fr) Utilisations d'inhibiteurs de hsp90 marqués
WO2006071274A3 (fr) Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
WO2011009020A3 (fr) Composés et compositions pour une utilisation en photothérapie et dans le traitement d'une maladie néovasculaire oculaire et de cancers
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
WO2007050784A3 (fr) Traitement a base de combinaisons de medicaments a rapport fixe pour le traitement de tumeurs solides
NZ592641A (en) 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine, its salts, and uses in medical treatment
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
WO2006110175A3 (fr) Traitement combinant le bortezomib et un inhibiteur des kinases du recepteur du facteur de croissance epidermique
WO2008060899A3 (fr) Procédés de dépistage et de traitement du cancer du sein
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
WO2006110176A3 (fr) Traitement combinant un rayonnement et un inhibiteur de kinase du recepteur du facteur de croissance epidermique
WO2008025033A3 (fr) traitement de l'anémie aplastique
EP1781296A4 (fr) Derives de quinazoline, utilisation de ces derniers dans le traitement de la thrombocythemie
WO2011051280A8 (fr) Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation
WO2004073649A3 (fr) Peptide clk et peptide slk
WO2008014386A3 (fr) Traitement de tumeurs chez des patients pédiatriques avec des antagonistes des récepteurs du facteur de croissance épidermique
WO2011051271A3 (fr) Marqueurs de tumeur de la prostate et méthodes d'utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780024999.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813400

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2654911

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: CR2008-010486

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 12008502750

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2007279261

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008121988

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 573608

Country of ref document: NZ

Ref document number: 195938

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 08133771

Country of ref document: CO

Ref document number: MX/A/2008/016187

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007813400

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2008000751

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 5258/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009522001

Country of ref document: JP

Ref document number: 1020087031606

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200870603

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2007279261

Country of ref document: AU

Date of ref document: 20070726

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: PI0712368

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081219